Taking aim at mutant genes to treat melanoma

After many years of standstill and unsuccessful attempts, therapeutic advances have significantly improved the survival of patients with melanoma.
On target bullseye

Since 2010, there has been a massive paradigm shift in systemic melanoma therapy.

Before this, no survival benefits had been demonstrated throughout a variety of clinical trials.

Prognosis for metastatic melanoma patients was desperate, with a median overall survival of only a few months.1